KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Sarepta Therapeutics (SRPT) over the last 13 years, with Q3 2025 value amounting to $237.9 million.

  • Sarepta Therapeutics' Short-term Investments fell 7622.11% to $237.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.9 million, marking a year-over-year decrease of 7622.11%. This contributed to the annual value of $251.8 million for FY2024, which is 7982.23% down from last year.
  • Sarepta Therapeutics' Short-term Investments amounted to $237.9 million in Q3 2025, which was down 7622.11% from $289.5 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Short-term Investments high stood at $1.2 billion for Q4 2023, and its period low was $30.0 million during Q2 2021.
  • Its 5-year average for Short-term Investments is $749.5 million, with a median of $1.0 billion in 2024.
  • Per our database at Business Quant, Sarepta Therapeutics' Short-term Investments crashed by 9288.0% in 2021 and then surged by 343166.67% in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Short-term Investments (Quarter) stood at $30.0 million in 2021, then soared by 3308.66% to $1.0 billion in 2022, then grew by 22.02% to $1.2 billion in 2023, then tumbled by 79.82% to $251.8 million in 2024, then dropped by 5.51% to $237.9 million in 2025.
  • Its last three reported values are $237.9 million in Q3 2025, $289.5 million for Q2 2025, and $281.9 million during Q1 2025.